{"analyses":[{"ciLowerLimit":"0","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"8","dispersionType":"STANDARD_DEVIATION","dispersionValue":"1.5","groupDescription":"Assessment of statistical differences in P16 expression between 3 groups. The immunohistochemical evaluation is done using German- semiquantitative scoring system. The score ranges from ( 0, 1,2,3,4,6,8,9 and 12). The data will entered on SPSS,version 24 as numbers. The test of significance is Kruskal Wallis was used to examine the Difference in Median between groups. Post-hoc test with Bonferroni Correction was used for Pairwise comparisons . A p-value \\< 0.05 was considered significant.","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.001","pValueComment":"The test of significance is Kruskal Wallis was used to examine the Difference in Median between groups. Post-hoc test with Bonferroni Correction was used for Pairwise comparisons . A p-value \\< 0.05 was considered significant.","paramType":"Median Difference (Final Values)","paramValue":"0.001","statisticalMethod":"Kruskal-Wallis"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"8","value":"7"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"6","value":"4"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"4","value":"0"}]}],"title":"P16 cytoplasmic expression"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"8","value":"6"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"5","value":"4"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"3","value":"0"}]}],"title":"P16 nuclear expression"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"20"}],"units":"Participants"}],"description":"For P16 IHC staining, the percentage of P16 positive cells and the location of positive signals (nuclear or cytoplasmic) were visually estimated for neoplastic components of all lesions. German Semi-quantitative scoring system were used to evaluate P16 expression as every tumor will be given a score according to the intensity of the cytoplasmic and nucleic staining (no staining = 0, weak staining = 1, moderate staining = 2, strong staining = 3) And the extent of stained cells (0% = 0, 1-10% = 1, 11-50% =2, 51-80% = 3, 81-100% = 4). The final immunoreactive score will be determined by multiplying the intensity scores with the extent of positivity scores of stained cells, with the minimum score of 0 and a maximum score of 12 ( score 0, 1,2,3,4,6,8,9 and 12).","dispersionType":"Full Range","groups":[{"description":"22 cases of malignant ovarian germ cell tumors ; include Dysgerminoma , yolk sac tumor and immature teratomas will be treated by anti P16 antibody and Ki67 antibody.\n\np16INK4a Recombinant Rabbit Monoclonal Antibody (RM267): Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).Additional step for malignant cases , sections were treated by Ki67 antibody.","id":"OG000","title":"Malignant Ovarian Germ Cell Tumors ( MOGCTs)."},{"description":"20 cases of mature teratomas will be treated by anti P16 antibody .\n\np16INK4a Recombinant Rabbit Monoclonal Antibody (RM267): Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).Additional step for malignant cases , sections were treated by Ki67 antibody.","id":"OG001","title":"Mature Cystic Teratomas."},{"description":"20 cases of normally apparent ovaries will be treated by anti P16 antibody .\n\np16INK4a Recombinant Rabbit Monoclonal Antibody (RM267): Treatment of slides that cut from paraffin embedded blocks related to groups by immunohistochemical method by p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267).Additional step for malignant cases , sections were treated by Ki67 antibody.","id":"OG002","title":"Normally Apparent Ovaries."}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Antibody exposure overnight, assessed up to 3 days for each run of sections assessed.","title":"P16 Evaluation in Ovarian Germ Cell Tumors","type":"PRIMARY","unitOfMeasure":"units on a scale"}